MPM Oncology Impact Management »

Adaptimmune Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $4.0M 5.1M 0.78
2023-06-30 $4.7M 5.1M 0.93

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Olema Pharmaceuticals Common (OLMA)
Geron Corporation Common (GERN)
Repare Therapeutics Common (RPTX)
iTeos Therapeutics Common (ITOS)
Intellia Therapeutics Common (NTLA)
Moonlake Immunotherapeutics Common (MLTX)
Iovance Biotherapeutics Common (IOVA)
Crinetics Pharmaceuticals Common (CRNX)
Insmed Incorporated Common (INSM)
Structure Therapeutics Common (GPCR)
Verve Therapeutics Common (VERV)
Relay Therapeutics Common (RLAY)
Regenxbio Common (RGNX)
Cymabay Therapeutics Common

View all positions for MPM Oncology Impact Management

Top funds holding Adaptimmune Therapeutics

NEA Management Company
Baillie Gifford & Co
Long Focus Capital Management
Baker Bros. Advisors
Partner Fund Management
Bank of America Corporation
Tang Capital Management
Citadel Advisors
Syncona Portfolio
Jpmorgan Chase & Co
Redmile Group
GSA Capital Partners
Acuitas Investments
Millennium Management
DAFNA Capital Management

View all funds holding Adaptimmune Therapeutics